Camlin Fine Sciences Limited (BOM:532834)
India
· Delayed Price · Currency is INR | Market Cap | 23.92B |
| Revenue (ttm) | 17.78B |
| Net Income (ttm) | -612.99M |
| Shares Out | 192.09M |
| EPS (ttm) | -3.28 |
| PE Ratio | n/a |
| Forward PE | 34.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,308 |
| Average Volume | 126,877 |
| Open | 129.69 |
| Previous Close | 127.60 |
| Day's Range | 123.16 - 130.00 |
| 52-Week Range | 96.30 - 334.70 |
| Beta | 0.53 |
| RSI | 58.50 |
| Earnings Date | May 18, 2026 |
About Camlin Fine Sciences
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hy... [Read more]
Financial Performance
In fiscal year 2025, Camlin Fine Sciences's revenue was 16.67 billion, an increase of 14.62% compared to the previous year's 14.54 billion. Losses were -1.39 billion, 49.9% more than in 2024.
Financial StatementsNews
Camlin Fine Sciences Ltd (BOM:532834) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst ...
Camlin Fine Sciences Ltd (BOM:532834) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Challenges
Q3 2026 Camlin Fine Sciences Ltd Earnings Call Transcript
Q3 2026 Camlin Fine Sciences Ltd Earnings Call Transcript
Camlin Fine Sciences Transcript: Q3 25/26
Q3 revenue grew 6% year-over-year to INR 572 crore, with blends up 11% and vanillin sales managed for future tariff benefits. Gross margin declined to 45%, but FY 2027 guidance targets 4,000 tons vanillin, 25% blends growth, and improved margins.
Camlin Fine Sciences Transcript: Q2 25/26
Quarterly revenue grew 8.6% sequentially, with strong volume recovery and improved margins, despite ongoing tariff and realization pressures. Management reaffirmed full-year guidance and expects further growth from field force expansion and a new acquisition in France.
Camlin Fine Sciences Transcript: Q1 25/26
Q1 FY2026 saw revenue and EBITDA decline due to plant shutdowns and one-time costs, but the blends business continued strong growth. Vanillin production ran at 50% capacity, with tariffs and channel inventory impacting near-term outlook. Gross margins are expected to stabilize at 40%-45%.
Camlin Fine Sciences Transcript: Q4 24/25
Annual revenue grew 15% to INR 1,666 crore, with strong blend and vanillin segment growth. Discontinued operations' cash burn will reduce, and vanillin capacity utilization is set to reach 100% in two years, benefiting from anti-dumping duties in key markets.
Camlin Fine Sciences Transcript: Q3 24/25
Revenue and margins improved year-over-year, with vanillin and blends segments showing strong growth. Anti-dumping duties are boosting vanillin prices, while rights issue proceeds have strengthened the balance sheet and reduced debt.
Camlin Fine Sciences Q3 FY25 results: Revenue rises 8.7% YoY to Rs 435.5 crore, net loss at Rs 158.2 crore
The company attributed the net loss to several factors, including impairments on overseas subsidiaries, non-cash adjustments, and foreign exchange losses.
Top stocks to buy today: Stock recommendations for February 7, 2025
Stock market recommendations: Bajaj Broking Research recommends buying Camlin Fine Sciences and Equinox India Developments for favorable stock positions. The Nifty is expected to sustain a positive bi...
Camlin Fine Sciences Transcript: Q2 24/25
Revenue grew 6.9% sequentially to INR 422 crore, with gross margin at 48.2% and EBITDA margin at 10.2%. Major impairments in Europe and China totaled INR 151 crore, but core businesses—aroma and blends—are expanding, with double-digit EBITDA margins expected to sustain.
Q1 2025 Camlin Fine Sciences Ltd Earnings Call Transcript
Q1 2025 Camlin Fine Sciences Ltd Earnings Call Transcript
Camlin Fine Sciences Transcript: Q1 24/25
Q1 FY25 saw stable revenues and improved margins despite global demand weakness and pricing headwinds. Blends business grew strongly, while European operations remained a drag. Management expects double-digit EBITDA margins for FY25, aided by acquisitions and anti-dumping actions.